Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer

详细信息    查看全文

• 作者：Jeffrey R. Infante ; Amita Patnaik…
• 关键词：Eg5 ; Kinesin spindle protein (KSP) ; KSP inhibitor ; Antimitotic ; Phase 1
• 刊名：Cancer Chemotherapy and Pharmacology
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：79
• 期：2
• 页码：315-326
• 全文大小：<len>
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Oncology; Pharmacology/Toxicology; Cancer Research;
• 出版者：Springer Berlin Heidelberg
• ISSN：1432-0843
• 卷排序：79

文摘

PurposeThis first-in-human report examined the recommended Phase 2 dose and schedule of litronesib, a selective allosteric kinesin Eg5 inhibitor.